Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia

BACKGROUND: The majority of acute myeloid leukaemia (AML) patients are over sixty years of age. With current treatment regimens, survival rates amongst these, and also those younger patients who relapse, remain dismal and novel therapies are urgently required. In particular, therapies that have anti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Khanim, Farhat L., Hayden, Rachel E., Birtwistle, Jane, Lodi, Alessia, Tiziani, Stefano, Davies, Nicholas J., Ride, Jon P., Viant, Mark R., Gunther, Ulrich L., Mountford, Joanne C., Schrewe, Heinrich, Green, Richard M., Murray, Jim A., Drayson, Mark T., Bunce, Chris M.
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2785482/
https://ncbi.nlm.nih.gov/pubmed/19997560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0008147
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares